Patricia Coyle, MD

home / authors / patricia-coyle-md

Articles

Final Thoughts: Improving QoL in Multiple Sclerosis

Final Thoughts: Improving QoL in Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Optimistic Outlook in Treating Multiple Sclerosis

Optimistic Outlook in Treating Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Patient Support Networks for Multiple Sclerosis

Patient Support Networks for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
OPTIMUM Trial for Multiple Sclerosis

OPTIMUM Trial for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
TRIUMPHANT-MS Trial for Multiple Sclerosis

TRIUMPHANT-MS Trial for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Multiple Sclerosis Fatigue

Multiple Sclerosis Fatigue

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Quality of Life Issues:  Cognitive Changes with MS

Quality of Life Issues:  Cognitive Changes with MS

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Patient’s Journey of Therapies for Multiple Sclerosis

Patient’s Journey of Therapies for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Treatment Options Available for Multiple Sclerosis

Treatment Options Available for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Managing Psychological Symptoms of Multiple Sclerosis

Managing Psychological Symptoms of Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Psychological Impact of Multiple Sclerosis

Psychological Impact of Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 3rd 2021
Patient’s Journey: Diagnosis of Multiple Sclerosis

Patient’s Journey: Diagnosis of Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
January 25th 2021
The Future of Treating Multiple Sclerosis

The Future of Treating Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Decision-Making Process for Treating Multiple Sclerosis

Decision-Making Process for Treating Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Switching Therapies in Multiple Sclerosis

Switching Therapies in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Ozanimod in Multiple Sclerosis

Role of Ozanimod in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Diroximel Fumarate in Multiple Sclerosis

Role of Diroximel Fumarate in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Ocrelizumab in Europe for Multiple Sclerosis

Role of Ocrelizumab in Europe for Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Ocrelizumab for the Treatment of Multiple Sclerosis

Ocrelizumab for the Treatment of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Siponimod in Multiple Sclerosis

Role of Siponimod in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Treating With Cladribine in Multiple Sclerosis

Treating With Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Clinical Trials for Cladribine in Multiple Sclerosis

Clinical Trials for Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
The Use of Glatiramer Acetate in Multiple Sclerosis

The Use of Glatiramer Acetate in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
The Use of Interferon in Multiple Sclerosis

The Use of Interferon in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
First-Line Therapies for Relapsing Multiple Sclerosis

First-Line Therapies for Relapsing Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Clinically Isolated Syndrome Versus Multiple Sclerosis

Clinically Isolated Syndrome Versus Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
MOG-IgG in Multiple Sclerosis

MOG-IgG in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Differential Diagnosis of Multiple Sclerosis

Differential Diagnosis of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Diagnosis of Multiple Sclerosis: The McDonald Criteria

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Patricia Coyle, MD: Multiple Sclerosis Symptom Management

Patricia Coyle, MD: Multiple Sclerosis Symptom Management

Patricia Coyle, MD
September 18th 2018

Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.

12>

Latest Updated Articles

Jannis Müller, MD, MSc (Credit: LinkedIn)
Published: May 14th 2025 | Updated: May 16th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on Term
Giulia Fadda, MD (Credit: Ottawa Hospital Research Institute)
Published: May 12th 2025 | Updated: May 13th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack Severity
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
Published: March 4th 2025 | Updated: March 19th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
Published: January 30th 2025 | Updated: February 21st 2025
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
Published: February 15th 2025 | Updated: February 18th 2025
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
© 2025 MJH Life Sciences

All rights reserved.